TRNS Stock Analysis
TR
Avoid
Based on Eyestock quantitative analysis, TRNS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Transcat, Inc. engages in provision of calibration and laboratory instrument services. The company is headquartered in Rochester, New York and currently employs 918 full-time employees. The firm is focused on providing services and products to industries, particularly the life science industry, which includes pharmaceutical, biotechnology, medical device, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. The firm operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualifications, preventative maintenance, consulting and other related services. The Distribution segment sells and rents national and brand instruments to customers globally. The firm provides periodic on-site services, mobile calibration services, pickup and delivery, and in-house services at its calibration service centers. In addition, it operates calibration labs in 21 imbedded customer-site locations. The firm also has the assets of e2b calibration.